October 2, 2026

ADA-EASD 2026 Type 2 Diabetes Consensus, Ribupatide in PMOS, Vyepti After CGRP Failure, EVX-01 Peptide Vaccine

ADA and EASD publish their 2026 type 2 diabetes consensus, ribupatide cuts weight up to 20% in women with PMOS, and Vyepti helps after CGRP failure.

6 stories · Covering research, clinical-trials

Editor's Note

EASD closed on Friday with the field's new rulebook: the 2026 ADA-EASD consensus moves SGLT2 inhibitors and GLP-1-based drugs earlier in type 2 diabetes, tailored to heart and kidney risk rather than blood sugar alone. The meeting's last data included a Chinese Phase 2 trial in which ribupatide cut weight by up to 20.2% in women with PMOS and made menstrual cycles more frequent, and animal data from Ascletis suggesting its amylin and GLP-1/GIP combination might one day be dosed monthly. An NYU Langone specialty-pharmacy analysis, in which only 3.9% of GLP-1 starters stopped within a year, came from one organization with pharmacist follow-up and no comparison group. Outside metabolism, Lundbeck's open-label THRIVE trial found Vyepti helped 60% of migraine patients who had already had an inadequate response to a CGRP drug, and Evaxion said it will bring new immune data for its personalized peptide vaccine EVX-01 to the SITC meeting in November.

Research

ADA and EASD Publish 2026 Type 2 Diabetes Consensus Calling for Earlier SGLT2 Inhibitor and GLP-1-Based Therapy

The American Diabetes Association and the European Association for the Study of Diabetes published their 2026 consensus report on managing type 2 diabetes in non-pregnant adults on Friday, October 2, 2026, in Diabetes Care and Diabetologia, presenting it at EASD in Milan; it updates the 2022 report. Chaired by John Buse and Melanie Davies, it calls for earlier use of glucose-lowering medicines to prevent complications and earlier use of SGLT2 inhibitors and GLP-1-based therapies to modify disease and reduce complication risk, tailored to each person's cardiovascular and kidney risk. It also sets individualized weight-management goals and gives more attention to coexisting conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD).

#type-2-diabetes #glp-1 #easd-2026

Clinical Trials

Hengrui's Ribupatide Cuts Weight Up to 20.2% and Increases Menstrual Frequency in Phase 2 Trial in Women With PMOS

A Phase 2 trial of ribupatide, the weekly GLP-1/GIP dual agonist injection that Hengrui licensed to Kailera Therapeutics outside Greater China, enrolled 158 Chinese women aged 18 to 40 with obesity or overweight and polyendocrine metabolic ovarian syndrome (PMOS). After 32 weeks, weight fell 10% on 1 mg, 15.1% on 2 mg, and 20.2% on 4 mg versus 2.6% on placebo, according to an EASD abstract reported by BioSpace on Friday, October 2, 2026. All three ribupatide groups had more frequent menstrual cycles, while cycles became less frequent on placebo, and there were no serious adverse events or adverse events that led to stopping the study.

#ribupatide #hengrui #easd-2026

Research

NYU Langone Specialty Pharmacy Analysis Finds 3.9% of 2,943 GLP-1 Starters Stopped Within a Year

Two retrospective analyses by Shields Health Solutions and partner health systems, presented at the NASP inSPire2026 specialty pharmacy meeting (September 22-25) and reported by AJMC on September 25, 2026, examined GLP-1 therapy managed by health-system specialty pharmacies. At NYU Langone Health, 115 of 2,943 adults (83.4% commercially insured) who started injectable liraglutide, semaglutide, dulaglutide, or tirzepatide between August 2022 and May 2025 stopped within a year (3.9%), with stopping defined as at least 70 days without medication on hand; rates were 1.8% for tirzepatide, 6.1% for semaglutide, 5.9% for dulaglutide, and 25% for liraglutide. A second analysis of 1,707 patients found a median of five days from prescription to first dispense, prior authorization for 95%, and a median out-of-pocket cost of $24.98; the authors noted the single-organization design and lack of a comparison group.

#semaglutide #tirzepatide #specialty-pharmacy

Research

Ascletis Reports Month-Long Half-Lives in Monkeys for Its Amylin and GLP-1/GIP Peptide Combination ASC36_35FDC

Ascletis Pharma announced on Friday, October 2, 2026 preclinical data presented at EASD for ASC36_35FDC, a fixed-dose injection that combines its peptide amylin receptor agonist ASC36 with its peptide GLP-1/GIP receptor agonist ASC35. In non-human primates, the two components had half-lives of about 781 hours (33 days) and 721 hours (30 days), which the company says could support once-monthly and possibly once-quarterly dosing in people. In diet-induced obese rats, the combination cut body weight 24.8% at day 14 versus 12.5% for an eloralintide/tirzepatide combination and 16.8% for MET-233i/tirzepatide at the same dosing; the results come from animals only.

#ascletis #asc36 #amylin #preclinical #easd-2026

Clinical Trials

Evaxion to Present New Immune Data for Its AI-Designed Personalized Peptide Vaccine EVX-01 Plus Keytruda in Melanoma at SITC 2026

Evaxion said on Friday, October 2, 2026 that it will present new immune data from its Phase 2 trial of EVX-01, a personalized, AI-designed peptide cancer vaccine given with Merck's Keytruda (pembrolizumab) to 16 patients with advanced melanoma, at the Society for Immunotherapy of Cancer meeting in Phoenix, with an oral presentation on November 6. Previously reported two-year results showed objective responses in 12 of 16 patients (75%), including four complete responses, and tumor-specific immune responses to 86% of the vaccine's neoantigen targets. Each patient receives a vaccine designed and manufactured from their own tumor's biology.

#evaxion #peptide-vaccine #melanoma

Clinical Trials

Lundbeck's Vyepti Leaves 60% of Migraine Patients 'Much Improved' After a Prior CGRP Drug Fell Short, in Open-Label Phase 4 THRIVE Trial

Lundbeck reported headline results on Thursday, October 1, 2026 from THRIVE, an open-label Phase 4 trial of Vyepti (eptinezumab), an antibody against the neuropeptide CGRP, in 164 adults with at least eight monthly migraine days whose migraine had responded inadequately to one prior CGRP-targeting preventive, either a subcutaneous antibody or a gepant. Patients received 100 mg at baseline and 300 mg at week 12; at week 24, 60% rated themselves much or very much improved on the Patient Global Impression of Change scale, up from 44% at week 12, and 84% completed the study. There was no placebo group, and Lundbeck said no new safety signals were seen.

#lundbeck #eptinezumab #cgrp #migraine